Tags

Type your tag names separated by a space and hit enter

A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx.
Vaccine. 2010 Mar 16; 28(13):2510-6.V

Abstract

Nasal vaccination is an effective therapeutic regimen for preventing otitis media. In the development of nasal vaccine, an appropriate adjuvant is required. In the present study, we examined the efficacy of fms-like tyrosine kinase receptor-3 ligand (Flt3L) as a mucosal adjuvant. Flt3L was administered intranasally or peritoneally to mice, which were then immunized intranasally with P6 protein of nontypeable Haemophilus influenzae (NTHi), and P6-specific immune responses were examined. In addition, NTHi challenges were performed and the level of NTHi was quantified in nasal washes. Nasal application of Flt3L induced an increase in the number of dendritic cells in nasal-associated lymphoid tissue. P6-specific nasal wash immunoglobulin (Ig)A and serum IgG titers were elevated significantly after nasal immunization. Enhanced NTHi clearance from the nasopharynx was also observed. The effect of nasal vaccination with P6 combined with nasal Flt3L application was prolonged. These results indicate the potential of Flt3L as an effective mucosal adjuvant and suggest that nasal vaccination with P6 in combination with nasal Flt3L might be an effective regimen for the induction of NTHi-specific protective immunity.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Kodama S
Department of Otolaryngology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hazama-cho, Yufu, Oita 879-5593, Japan. satoruk@med.oita-u.ac.jp
Hirano T
No affiliation info available
Noda K
No affiliation info available
Abe N
No affiliation info available
Suzuki M
No affiliation info available

MeSH

Adjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsColony Count, MicrobialHaemophilus InfectionsHaemophilus VaccinesHaemophilus influenzaeImmunity, MucosalImmunoglobulin AImmunoglobulin GInjections, IntraperitonealMembrane ProteinsMiceMice, Inbred BALB CNasal CavityNasopharynx

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20117272

Citation

Kodama, Satoru, et al. "A Single Nasal Dose of Fms-like Tyrosine Kinase Receptor-3 Ligand, but Not Peritoneal Application, Enhances Nontypeable Haemophilus Influenzae-specific Long-term Mucosal Immune Responses in the Nasopharynx." Vaccine, vol. 28, no. 13, 2010, pp. 2510-6.
Kodama S, Hirano T, Noda K, et al. A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine. 2010;28(13):2510-6.
Kodama, S., Hirano, T., Noda, K., Abe, N., & Suzuki, M. (2010). A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine, 28(13), 2510-6. https://doi.org/10.1016/j.vaccine.2010.01.043
Kodama S, et al. A Single Nasal Dose of Fms-like Tyrosine Kinase Receptor-3 Ligand, but Not Peritoneal Application, Enhances Nontypeable Haemophilus Influenzae-specific Long-term Mucosal Immune Responses in the Nasopharynx. Vaccine. 2010 Mar 16;28(13):2510-6. PubMed PMID: 20117272.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. AU - Kodama,Satoru, AU - Hirano,Takashi, AU - Noda,Kenji, AU - Abe,Nobuyuki, AU - Suzuki,Masashi, Y1 - 2010/01/29/ PY - 2009/10/31/received PY - 2009/12/27/revised PY - 2010/01/16/accepted PY - 2010/2/2/entrez PY - 2010/2/2/pubmed PY - 2010/5/21/medline SP - 2510 EP - 6 JF - Vaccine JO - Vaccine VL - 28 IS - 13 N2 - Nasal vaccination is an effective therapeutic regimen for preventing otitis media. In the development of nasal vaccine, an appropriate adjuvant is required. In the present study, we examined the efficacy of fms-like tyrosine kinase receptor-3 ligand (Flt3L) as a mucosal adjuvant. Flt3L was administered intranasally or peritoneally to mice, which were then immunized intranasally with P6 protein of nontypeable Haemophilus influenzae (NTHi), and P6-specific immune responses were examined. In addition, NTHi challenges were performed and the level of NTHi was quantified in nasal washes. Nasal application of Flt3L induced an increase in the number of dendritic cells in nasal-associated lymphoid tissue. P6-specific nasal wash immunoglobulin (Ig)A and serum IgG titers were elevated significantly after nasal immunization. Enhanced NTHi clearance from the nasopharynx was also observed. The effect of nasal vaccination with P6 combined with nasal Flt3L application was prolonged. These results indicate the potential of Flt3L as an effective mucosal adjuvant and suggest that nasal vaccination with P6 in combination with nasal Flt3L might be an effective regimen for the induction of NTHi-specific protective immunity. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/20117272/A_single_nasal_dose_of_fms_like_tyrosine_kinase_receptor_3_ligand_but_not_peritoneal_application_enhances_nontypeable_Haemophilus_influenzae_specific_long_term_mucosal_immune_responses_in_the_nasopharynx_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)00075-7 DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓10]

Related Citations

More